Article
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Blood - 15 Jul 2007
Pfeifer Heike, Wassmann Barbara, Pavlova Anna, Wunderle Lydia, Oldenburg Johannes, Binckebanck Anja, Lange Thoralf, Hochhaus Andreas, Wystub Silvia, Brück Patrick, Hoelzer Dieter, Ottmann Oliver G
Abstract excerpt
Acquired imatinib resistance in advanced Philadelphia-positive acute lymphoblastic leukemia (Ph(+) ALL) has been associated with mutations in the kinase domain (KD) of BCR-ABL. We examined the prevalence of KD mutations in newly diagnosed and imatinib-naive Ph(+) ALL patients and assessed their clinical relevance in the setting of uniform frontline therapy with imatinib in combination with chemotherapy. Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.